<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>platinum-based chemotherapy &#8211; BIOENGINEER.ORG</title>
	<atom:link href="https://bioengineer.org/tag/platinum-based-chemotherapy/feed/" rel="self" type="application/rss+xml" />
	<link>https://bioengineer.org</link>
	<description>Bioengineering</description>
	<lastBuildDate>Sun, 14 Jan 2024 17:49:50 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>
	hourly	</sy:updatePeriod>
	<sy:updateFrequency>
	1	</sy:updateFrequency>
	<generator>https://wordpress.org/?v=7.0</generator>

<image>
	<url>https://bioengineer.org/wp-content/uploads/2019/09/cropped-bioengineering-32x32.png</url>
	<title>platinum-based chemotherapy &#8211; BIOENGINEER.ORG</title>
	<link>https://bioengineer.org</link>
	<width>32</width>
	<height>32</height>
</image> 
<site xmlns="com-wordpress:feed-additions:1">72741379</site>	<item>
		<title>Advances in NSCLC Treatment &#8211; Overcoming Osimertinib Resistance and Exploring the Potential of Amivantamab and Lazertinib</title>
		<link>https://bioengineer.org/advances-in-nsclc-treatment-overcoming-osimertinib-resistance-and-exploring-the-potential-of-amivantamab-and-lazertinib/</link>
		
		<dc:creator><![CDATA[Bioengineer]]></dc:creator>
		<pubDate>Sun, 14 Jan 2024 17:49:34 +0000</pubDate>
				<category><![CDATA[Cancer]]></category>
		<category><![CDATA[amivantamab]]></category>
		<category><![CDATA[cancer research]]></category>
		<category><![CDATA[ctDNA analysis]]></category>
		<category><![CDATA[EGFR mutations]]></category>
		<category><![CDATA[EGFR TKIs]]></category>
		<category><![CDATA[lazertinib]]></category>
		<category><![CDATA[next-generation sequencing]]></category>
		<category><![CDATA[NSCLC]]></category>
		<category><![CDATA[oncology advancements]]></category>
		<category><![CDATA[osimertinib resistance]]></category>
		<category><![CDATA[platinum-based chemotherapy]]></category>
		<category><![CDATA[targeted therapy]]></category>
		<guid isPermaLink="false">https://bioengineer.org/?p=219304</guid>

					<description><![CDATA[In the ever-evolving landscape of cancer treatment, recent breakthroughs in the fight against non-small cell lung cancer (NSCLC) have brought new hope to patients and clinicians alike. At the forefront of these advancements is the remarkable progress in understanding and targeting mutations in the epidermal growth factor receptor (EGFR), which are among the most common [&#8230;]]]></description>
		
		
		
		<post-id xmlns="com-wordpress:feed-additions:1">219304</post-id>	</item>
	</channel>
</rss>
